A retrospective cohort analysis shows that pediatric patients with noninfectious uveitis face lower recurrence rates when ...

Adalimumab had superior efficacy and safety outcomes compared with secukinumab and bimekizumab for the treatment of hidradenitis suppurativa.

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort ...

US FDA designates Celltrion’s Yuflyma as an interchangeable biosimilar to Humira: Incheon, South Korea Wednesday, April 16, 2025, 16:00 Hrs [IST] Celltrion, Inc. announced that ...

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Dosage for Humira (adalimumab) may vary based on the condition it’s being used to treat. Also, your doctor may adjust your dosage over the course of your treatment. Be sure to take the Humira ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this consolidation of the drug supply chain could undercut competition.

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...